Abstract
Impact of organ function based standard exclusion criteria in diffuse large b-cell lymphoma (DLBCL) patients: Who gets left behind?
Journal of clinical oncology, Vol.38(15_suppl), pp.e14100-e14100
05/20/2020
DOI: 10.1200/JCO.2020.38.15_suppl.e14100
Abstract
e14100
Background: Only 3-5% of adult cancer patients in the US enroll in clinical trials. Patients with organ dysfunction are often excluded from clinical trials, regardless of specific drug metabolism or relative function of the organ. The ASCO and the US FDA recommend modernizing criteria related to baseline organ function and comorbidities. In hematological malignancies, often the disease itself is the reason for organ function derangement. In order to better inform clinical trial eligibility and improve participation in the future, we evaluated the impact of baseline organ function on the potential eligibility for clinical trial enrollment for real world patients with newly diagnosed DLBCL. Methods: Consecutive, newly diagnosed lymphoma patients were offered enrollment from 2002-2015 into the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence. This analysis is based on 1270 DLBCL patients receiving immunochemotherapy. Baseline organ function parameters were identified from the exclusion criteria for hemoglobin, absolute neutrophil count (ANC), platelet count, creatinine, and bilirubin reported in recent frontline trials in DLBCL (Table). Abstracted clinical labs from the MER were used to determine the percent of patients that would be excluded based on the criteria. Results: We determined that 11-23% of MER DLBCL patients receiving standard of care frontline therapy would have been excluded in the various trials utilizing baseline organ function alone (Table). Hemoglobin and renal function had the greatest impact on exclusion. Conclusions: Current national and international (phase II and III) trials are excluding up to 23% of patients from clinical trial participation based on organ function alone in DLBCL. These data will be useful in future clinical trial development to meet ASCO recommendations to increase trial accrual, while balancing the drug toxicities and patient safety. An online tool was developed based on these results to aid future trial development. [Table: see text]
Details
- Title: Subtitle
- Impact of organ function based standard exclusion criteria in diffuse large b-cell lymphoma (DLBCL) patients: Who gets left behind?
- Creators
- Arushi Khurana - Mayo ClinicRaphael Mwangi - Mayo ClinicGrzegorz S. Nowakowski - Mayo ClinicThomas Matthew Habermann - Mayo ClinicStephen M. Ansell - Mayo ClinicBetsy LaPlant - Mayo ClinicBrian K. Link - University of IowaJames Robert Cerhan - Mayo ClinicMatthew J. Maurer - Mayo ClinicThomas E. Witzig - Mayo Clinic
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.38(15_suppl), pp.e14100-e14100
- DOI
- 10.1200/JCO.2020.38.15_suppl.e14100
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: None
- Language
- English
- Date published
- 05/20/2020
- Academic Unit
- Epidemiology; Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362299302771
Metrics
7 Record Views